Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
The innovative basket study design of CIELO offers the opportunity to yield prospective, robust evidence, which may contribute to the development of evidence-based treatment recommendations for satralizumab in AIE.
Authors
- Jane St Lambert
- Sharmila Rajan
- Hideto Nakajima (ORCID: https://orcid.org/0000-0002-2154-9196)
- Jeffrey Marc Gelfand (ORCID: https://orcid.org/0000-0002-5121-3319)
- James Overell (ORCID: https://orcid.org/0000-0002-3998-9819)
- Sarosh R. Irani (ORCID: https://orcid.org/0000-0002-7667-9748)
- М.Э. Гафарова
- Amanda L. Piquet (ORCID: https://orcid.org/0000-0001-7349-6455)
- E. Ann Yeh (ORCID: https://orcid.org/0000-0002-5393-7417)
- Muna El-Khairi
- Hesham Abboud (ORCID: https://orcid.org/0000-0001-5346-8254)
- Sean Joseph Pittock (ORCID: https://orcid.org/0000-0002-6140-5584)
- Jiawei Wang (ORCID: https://orcid.org/0000-0002-8606-6873)
- Soon‐Tae Lee (ORCID: https://orcid.org/0000-0003-4767-7564)
- Jillian Smith
Institutions
- Nihon University (JP)
- Roche (Switzerland) (CH)
- Beijing Tongren Hospital (CN)
- Mayo Clinic (US)
- Capital Medical University (CN)
- University of Toronto (CA)
- University Hospitals of Cleveland (US)
- Hospital for Sick Children (CA)
- Seoul National University Hospital (KR)
- University of Oxford (GB)
- Roche (United Kingdom) (GB)
- SickKids Foundation (CA)
- Mayo Clinic in Florida (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2024-08-13
- DOI
- https://doi.org/10.3389/fneur.2024.1437913
- Citations
- 17
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.28
Funders
- F. Hoffmann-La Roche
- Medical Research Council